Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 24 January 2026 - 27 January 2026

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·
Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly shares slipped 0.1% to $1,062.87 in late morning trading Monday, extending last week’s decline. Investors are focused on the Feb. 4 earnings release and updates on obesity drug launches amid rising competition from Novo Nordisk. Early U.S. sales of Novo’s oral Wegovy and anticipation for Lilly’s orforglipron pill are drawing analyst attention. Legal and pricing pressures add uncertainty as both firms battle for market share.
26 January 2026
···
Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics shares rose 6.5% to $22.51 in early premarket trading Monday, following a 9.65% after-hours surge Friday ahead of new Elevidys trial data. Investors await three-year results from the Phase 3 EMBARK study in Duchenne muscular dystrophy, with safety concerns heightened after FDA restrictions and patient deaths. About 17,600 shares changed hands premarket, according to Public.com.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche participation shares closed Friday at 348.10 Swiss francs, up 0.06% and near a 52-week high. The company will report full-year 2025 results before the Swiss market opens on Jan. 29, followed by a management webcast. Investors are watching for 2026 guidance and updates on drug launches and diagnostics demand. The Swiss Market Index fell 0.61% Friday.
25 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and other firms of funding terrorism in Iraq. The ruling was announced after U.S. markets closed; AstraZeneca shares had closed up 1.37% in New York and 0.15% in London. The company plans to switch its U.S. listing from Nasdaq to NYSE on Jan. 30. Investors await Monday’s market reaction.
24 January 2026
··
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B shares closed up 1.17% at 401.35 crowns in Copenhagen, lifted by strong early U.S. demand for its new Wegovy pill. The company faces a new U.S. lawsuit alleging a “pay-for-delay” scheme for Victoza. Over 18,000 Wegovy pill prescriptions were reported in the U.S. since its Jan. 5 launch. Indian regulators approved local firms to make generic semaglutide ahead of the 2026 patent expiry.
24 January 2026
··
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Eli Lilly shares fell 2.1% to $1,064.29 Friday after analysts reported Novo Nordisk’s new Wegovy pill logged 18,410 U.S. prescriptions in its first full week. Lilly’s Q4 results are due Feb. 4. India approved local firms to make generic semaglutide ahead of its 2026 patent expiry. New data showed many patients did not quickly regain weight after stopping GLP-1 drugs.
24 January 2026
···
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta shares rose about 5% in after-hours trading Friday after the company announced it will release three-year Phase 3 data for its Duchenne gene therapy, Elevidys, on Jan. 26. The update follows recent FDA restrictions and safety warnings after deaths in non-ambulatory patients. Investors are watching for data on durability and safety. Sarepta will hold a webcast Monday morning to present the results.
24 January 2026
··
1 … 4 5 6 7 8 … 34

Stock Market Today

Oil stocks jump on Iran risk lift for crude — what to watch before Monday

Oil stocks jump on Iran risk lift for crude — what to watch before Monday

7 February 2026
U.S. oil stocks surged Friday as crude prices rose on renewed Middle East tensions. Exxon Mobil gained 2.0%, ConocoPhillips 2.5%, and Occidental Petroleum 2.7%. Refiners rallied after a national union deal eased strike risk, though BP’s Whiting plant faces a local dispute. Brent settled at $68.05 a barrel, up 0.74%.
Silver price rebound masks fresh stress after CME lifts margins again

Silver price rebound masks fresh stress after CME lifts margins again

7 February 2026
Spot silver surged 8.6% to $77.33 an ounce Friday after dropping below $65, but still lost over 8.7% for the week. CME Group raised margin requirements for COMEX silver futures to 18% from 15%, effective after Feb. 6. China’s UBS SDIC Silver Futures Fund hit its 10% down limit for a fifth session. Traders await key U.S. jobs and inflation data next week.
Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

7 February 2026
China’s central bank raised gold reserves for a 15th month in January, reaching 74.19 million ounces worth $369.58 billion. Gold prices swung sharply, hitting a record near $5,600 before dropping to $4,403.24. CME Group hiked COMEX gold futures margins to 9% after recent volatility. U.S. jobs and inflation data are due next week after a delay.
Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company forecast 2026 capital spending would jump to $200 billion, up more than 50% from 2025. The drop came as the Dow closed above 50,000 for the first time. Amazon reported fourth-quarter net sales up 14% to $213.4 billion and operating income at $25 billion. Trading in Amazon was volatile, with 179 million shares changing hands.
Go toTop